Lexapro and Multihance drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Lexapro (escitalopram oxalate) and Multihance (gadobenate dimeglumine). Common drug interactions include skin disorder among females and nephrogenic systemic fibrosis among males.

The phase IV clinical study analyzes what interactions people have when they take Lexapro and Multihance. It is created by eHealthMe based on reports of 64 people who take the same drugs from the FDA, and is updated regularly.

What is Lexapro?

Lexapro has active ingredients of escitalopram oxalate. It is often used in depression. eHealthMe is studying from 91,464 Lexapro users. Check the latest studies of Lexapro.

What is Multihance?

Multihance has active ingredients of gadobenate dimeglumine. eHealthMe is studying from 5,786 Multihance users. Check the latest studies of Multihance.

On Jul, 26, 2026

64 people who take Lexapro and Multihance together, and have interactions are studied.

Lexapro and Multihance drug interactions.

What are the common drug interactions of Lexapro and Multihance, by gender? *:

female:

Skin disorder (skin disease)
General physical health deterioration (weak health status)
Scar
Skin lesion
Gait disturbance
Joint stiffness
Pain in extremity
Arthritis (form of joint disorder that involves inflammation of one or more joints)
Asthenia (weakness)
Bone pain

male:

Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease)
Mobility decreased (ability to move is reduced)
Joint range of motion decreased (disease of joint movement)
Skin hypertrophy (skin cells enlarges)
Musculoskeletal stiffness (stiffness of the body's muscles, joints, tendons, ligaments and nerves)
Injury
General physical health deterioration (weak health status)
Pain in extremity
Extremity contracture (permanent shortening of a muscle or joint of arms and legs)
Fibrosis (formation of excess fibrous connective tissue in an organ or tissue)

What are the common drug interactions of Lexapro and Multihance, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

Anaphylactic reaction (serious allergic reaction)

20-29:

Arthralgia (joint pain)
Back pain
Extremity contracture (permanent shortening of a muscle or joint of arms and legs)
Fall
Joint lock
Musculoskeletal pain (pain affects the bones, muscles, ligaments, tendons, and nerves)
Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease)
Pain
Peroneal nerve palsy
Vascular calcification (deposits of calcium in the blood vessels)

30-39:

Mobility decreased (ability to move is reduced)
Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease)
Pain
Skin hypertrophy (skin cells enlarges)
Skin induration (an abnormally hard spot or area on the skin)
Arthralgia (joint pain)
Skin tightness
Extremity contracture (permanent shortening of a muscle or joint of arms and legs)
Joint range of motion decreased (disease of joint movement)
Pruritus (severe itching of the skin)

40-49:

Excoriation (to tear or wear off the skin of)
Extremity contracture (permanent shortening of a muscle or joint of arms and legs)
Injury
Insomnia (sleeplessness)
Joint range of motion decreased (disease of joint movement)
Joint stiffness
Lichenification (thickening and hardening of the skin)
Limb discomfort (discomfort in leg)
Lung disorder (lung disease)
Mobility decreased (ability to move is reduced)

50-59:

Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease)
Pain
Mobility decreased (ability to move is reduced)
Oedema peripheral (superficial swelling)
Scar
Fibrosis (formation of excess fibrous connective tissue in an organ or tissue)
General physical health deterioration (weak health status)
Skin tightness
Musculoskeletal stiffness (stiffness of the body's muscles, joints, tendons, ligaments and nerves)
Skin induration (an abnormally hard spot or area on the skin)

60+:

Arteriospasm coronary (spasm of the large- or medium-sized coronary arteries)
Cardio-respiratory arrest (sudden dysfunction of heart and lungs)
Rash maculo-papular (red area on the skin that is covered with small confluent bumps)
Skin discolouration (change of skin colour)
Skin induration (an abnormally hard spot or area on the skin)
Anaphylactic shock (severe and rapid and sometimes fatal hypersensitivity reaction to a substance)
Back pain
Hypoaesthesia (reduced sense of touch or sensation)
Joint swelling
Neck pain

What are the existing conditions these people have? *

Nuclear Magnetic Resonance Imaging Brain: 23 people, 35.94%
Diabetes: 10 people, 15.62%
Nuclear Magnetic Resonance Imaging Abdominal: 7 people, 10.94%
Pain: 5 people, 7.81%
Sleep Apnea Syndrome: 4 people, 6.25%
Headache (pain in head): 4 people, 6.25%
Brain Stem Syndrome: 4 people, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Lexapro and Multihance?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously